Mankind Pharma Ltd. (MANKIND)
NSE
2,265.00
-44.00 (-1.91%)
Closed
Sep 9, 2026
Day's Range
2,252.002,315.60
52 wk Range
1,909.702,674.00
Financial Statements - MANKIND - Mankind Pharma Ltd.
Revenue
142.77B▲ 17.0%
Net Income
19.38B▼ 3.6%Net Margin 13.6%
EBITDA
38.76B▲ 19.4%
Free Cash Flow
23.84B▲ 26.6%
Income Statement
| Period Ending | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|---|---|
| Sales | 142.77B | 122.07B | 103.34B | 87.49B | 77.81B | 62.14B |
| Cost of Goods | 41.49B | 35.69B | 32.68B | 29.62B | 24.70B | 18.24B |
| Gross Profit | 101.28B | 86.38B | 70.66B | 57.87B | 53.11B | 43.89B |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 28.35B | 25.16B | 22.34B | 16.37B | 18.78B | 16.06B |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | - | - | - | - | - | - |
| Pre Tax Income | 23.32B | 25.16B | 23.99B | 16.71B | 19.74B | 16.91B |
| Income Tax | 3.94B | 5.09B | 4.57B | 3.61B | 5.21B | 3.98B |
| Net Income | 19.38B | 20.11B | 19.41B | 13.09B | 14.52B | 12.93B |
| EPS Basic | 46.35 | 49.28 | 47.75 | 31.999403 | 35.784233 | 31.589204 |
| EPS Diluted | 46.28 | 49.19 | 47.68 | 31.999403 | 35.784233 | 31.589204 |
| Basic Shares Outstanding | 412.73M | 403.97M | 400.58M | 400.58M | 400.58M | 400.58M |
| Diluted Shares Outstanding | 412.73M | 403.97M | 400.58M | 400.58M | 400.58M | 400.58M |
| Ebit | 29.66B | 29.37B | 24.27B | 17.11B | 20.30B | 17.10B |
| Ebitda | 38.76B | 32.48B | 27.11B | 20.18B | 20.98B | 17.92B |
| Net Income Continuous Operations | 23.32B | 25.24B | 23.99B | 16.71B | 19.74B | 16.91B |
| Minority Interests | -251.70M | -201.60M | -288.75M | -278.16M | -194.81M | -276.07M |
| Preferred Stock Dividends | 0 | 0 | 0 | 0 | 0 | 0 |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
